Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
Clinical Nephrology. 01 May 2018;89(5):314-329
Renal dysfunction increases the risk of thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation(NVAF).
MATERIALS AND METHODS:
Adult NVAF patients with ≥ 6 months prior to first warfarin or rivaroxaban dispensing were selected from the IMS Health Real-World Data Adjudicated Claims database (05/2011 - 06/2015) with electronic medical records. Ischemic stroke events, thromboembolic events (venous thromboembolism, myocardial infarction, or ischemic stroke), and major bleeding events were compared between patients by renal function identified by 1) relevant ICD-9-CM diagnosis codes and 2) estimated creatinine clearance (eCrCl). Baseline confounders were adjusted using inverse probability of treatment weights.
The diagnosis-based analysis included 39,872 rivaroxaban and 48,637 warfarin users (3,572 and 8,230 with renal dysfunction, respectively). The eCrCl-based analysis included 874 rivaroxaban and 1,069 warfarin users (66 and 208 with eCrCl < 60 ml min, respectively). in the diagnosis-based analysis, rivaroxaban users with renal dysfunction had a significantly lower stroke rate (hr =" 0.55," p =" 0.0004)" compared to warfarin users; rivaroxaban users with and without renal dysfunction had significantly lower thromboembolic event rates (hr =" 0.62," p >< 0.0001; and hr =" 0.64," p >< 0.0001, respectively), and similar major bleeding rates to warfarin users. in the ecrcl-based analysis, rivaroxaban users with ecrcl ≥ 60 ml min had a significantly lower thromboembolic event rate, but other outcomes were not statistically significant.> 0.0001,> 0.0001;> 60>
Rivaroxaban-treated NVAF patients with diagnosed renal dysfunction had a significantly lower stroke rate compared to warfarin-treated patients. Regardless of renal dysfunction diagnoses, rivaroxaban users had lower thromboembolic event rates compared to warfarin users, and a similar rate of major bleeding. eCrCl-based analysis was limited by a small sample size.